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Introduction
Over the last years medicine has progressed very rap-
idly. Communicable diseases, which were the leading 
causes of mortalities, are not anymore, especially in 
developed countries. Currently, non-communicable dis-
eases are more prevalent, and most of them are related 
to changes in our daily habits and degenerative process-
es. Most of these diseases are chronic, need continuous 
care and treatment with limited improvement and high 
costs [1-3]. 
The General Assembly of the United Nations in its reso-
lution 65/238 recognized the primary role and responsi-
bility of Governments in responding to the challenge of 
non-communicable diseases and the essential need for 
the efforts and engagement of all sectors of society to 
generate an effective response [2].
Special emphasis has been concentrated on pharmaco-
logical treatments for most of chronic non-communica-
ble diseases with the challenge to discover new drugs for 
treating, in most cases, chronic irreversible degenerative 
diseases associated with aging. Little care was given to 
non-pharmacological lines of treatment [3]. 
Arterial hypertension 
Worldwide hypertension is the most frequent chronic 
disease among aged population It is estimated that 
35% of the general population over 40 years old suf-
fer idiopathic arterial hypertension and need treatment 
for life  [4,  5]. Over the last years pharmacological 
treatment has revolutionized rapidly. Angiotensin-
converting-enzyme inhibitors (ACEIs) have replaced 
beta-blockers in many cases. The current scientific 
debate is about indications, effectiveness, safety and 
cost-effectiveness of angiotensin receptor blocker 
(ARB) and AECI. Recently ARB is taking its place 
between known antihypertensive drugs especially in 
patients with other chronic diseases like renal insuf-
ficiency  [6,  7]. Non-pharmacological measures for 
treatment of hypertension are well-known and include 
diet control with low salt diet and cholesterol diet, 
tobacco cessation, weight control and physical exer-
cises [8-11]. It is estimated that 30% of hypertensive 
patients can control their blood pressure following 
non-pharmacological measures without the need for 
any antihypertensive drugs. Little attention is given to 
these basic non-pharmacological measures [12].
Diabetes mellitus
Over the last 30 years the number of Diabetes Mel-
litus (DM) patients and its prevalence are rapidly ris-
ing [13]. Ginter and Simko (2010) reported that in the 
second half of the 20th century it became obvious that a 
relentless increase in DM type 2 affecting the economi-
cally affluent countries is gradually afflicting also the 
developing world [14]. Oral antidiabetics drugs are vari-
ous and are very effective in DM type 2. However, all 
these drugs have several side effects, which are usually 
related to other underlying pathologies in the same pa-
tient [15]. DM type I is treated with insulin, which has 
been revolutionized over the last 10 years, with various 
forms of insulin and modes of administration [14, 16]. 
ShoRt Review
Health promotion or pharmacological treatment  
for chronic diseases?
M.F. ALLAM, M.A. ORTIZ ARJONA
South Cordoba Health District, Spain
Key words
COPD	•	DM	•	Hypertension	•	Obesity	•	Smoking	•	Non-communicable diseases
Summary
Over the last years medicine has progressed very rapidly. Com-
municable diseases, which were the leading causes of mortali-
ties, are not anymore, especially in developed countries. Cur-
rently, non-communicable diseases are more prevalent, and 
most of them are related to changes in our daily habits and 
degenerative processes. Most of these diseases are chronic, 
need continuous care and treatment with limited improvement 
and high costs. The General Assembly of the United Nations in 
its resolution 65/238 recognized the primary role and respon-
sibility of Governments in responding to the challenge of non-
communicable diseases and the essential need for the efforts 
and engagement of all sectors of society to generate an effec-
tive response. Special emphasis has been concentrated on phar-
macological treatments for most of chronic non-communicable 
diseases with the challenge to discover new drugs for treating, 
in most cases, chronic irreversible degenerative diseases asso-
ciated with aging. Little care was given to non-pharmacological 
lines of treatment. 
J prev med hyg 2013; 54: 11-13
M.F. AllAM, M.A. Ortiz ArjOnA
12
Non-pharmacological measures for control of blood 
glucose in diabetics, like diet and weight controls and 
regular physical exercise are hardly adopted by these pa-
tients [13, 16, 17]. 
Obesity
Obesity is the new epidemic of the 21st Century. It is es-
timated that in Western Countries > 40% of the general 
population are over weight. The raising incidence and 
prevalence of this morbidity is alarming. Junk food, high 
carbohydrate and fat diet and lack of physical exercise 
are the main risk factors for this epidemic [13]. 
Of no doubt diet control and physical exercise could re-
solve this health problem [18]. Over the last years, sev-
eral drugs were used to control weight, like Thyroxin and 
Metformine and new drugs like Litramine. Most of stud-
ies have shown that these drugs are not completely safe 
and could produce several side effects. Complications 
related to the use of these drugs are reported [13]. Other 
measures to treat obesity include surgical intervention 
like stomach reduction, liposuction and intestinal anas-
tomosis. Recent debates discuss severe complications 
and mortalities related to these surgical operations [19]. 
Chronic obstructive pulmonary diseases 
Smoking is the epidemic of the 20th Century. After 1950s 
tobacco smoking prevalence reached 45% of the general 
population in many western Countries  [20]. Currently 
chronic obstructive pulmonary diseases (COPD) is the 
second cause of mortalities in most Western Countries. 
Most of COPD patients are ex-smokers or even cur-
rent smokers [21]. Treatment of COPD has been revo-
lutionized over the last few years. Treatment measures 
include bronchodilators with sympathomimetics and 
antiparasympathomimetics, together with corticoster-
oids in the form of oral, injection and inhalation therapy. 
Side effects related to corticosteroids use like iatrogenic 
hypertension, and iatrogenic DM are well known [22]. 
Tiotropium is one of the specific treatments to delay the 
progress of the disease and to improve the pulmonary 
functions. Recent meta-analysis reported a 52% in-
creased risk of mortality associated with tiotropium mist 
inhaler in patients with COPD  [23]. Although weight 
reduction, physical exercise and pulmonary exercise in 
specific have been proved to be effective and improve 
pulmonary function tests by 30-40%, the use of pharma-
cological treatment in COPD is by far more numerous 
than non-pharmacological measures [22]. 
Discussion and conclusion 
In 2010, the Spanish National Health Service (NHS) 
paid for 958 million prescriptions. Most of these pre-
scriptions were realized at primary healthcare. Accord-
ing to the Spanish NHS, areas requiring improvement 
in primary care prescription include over-treatment of 
patients in low risk situations, poor patient information, 
polymedication and the appreciable percentage of pre-
ventable adverse effects [24].
Over the past few decades, developed countries have 
achieved remarkable improvements in terms of their life 
expectancy, with growing number of third age popula-
tion. Most older patients do have several concomitant 
chronic conditions and receive treatment mainly at pri-
mary healthcare by General Practitioners/Family Phy-
sicians. Multiple co-morbidities of older patients are 
usually associated with increased use of health care re-
sources, multiple health care providers, polymedication 
and an overall increased risk of adverse events [25].
A recent retrospective observational study performed in 
Croatia from March 2005 to December 2008, showed 
that polymedication leaded to serious adverse drug reac-
tions and deaths. This study reported 2076 adverse drug 
reactions, 1209 of which (58.2%) involved more than 
one drug [26].
In conclusion, we currently look for pharmacological 
and surgical measures to treat most of chronic non-
infectious diseases, as rapid and easy measures ignor-
ing their side effects and costs, rather than adopting 
healthy habits and non-pharmacological measures.
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